The risk and benefit profiles of US-eligible lung cancer screening attendees vs nonattendees
Open Access
- 27 June 2024
- journal article
- research article
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 116 (12) , 1896-1903
Abstract
Background: The US Preventive Services Task Force (USPSTF) recommend lung cancer screening for individuals aged 50-80 years with at least 20 pack-years and no more than 15 quit-years, but uptake is low. The risk and benefit profiles of screening attendees are unknown; consequently, the impact and lost opportunity of ongoing lung cancer screening in the United States remains unclear. Methods: We estimated lung cancer death risk (using the Lung Cancer Death Risk Assessment Tool) and life gained from screening (using the Life Years Gained From Screening-Computed Tomography model) for individuals aged 50-79 years who ever-smoked in the US representative 2022 Behavioral Risk Factor Surveillance System. We compared lung cancer death risk and life gained among USPSTF-eligible individuals by screening status (self-reported screened vs not screened in past year) and estimated the number of lung cancer deaths averted and life-years gained under current screening levels and if everyone eligible was screened. Results: USPSTF eligibility was 33.7% (95% confidence interval [CI] = 33.1% to 34.4%), of whom 17.9% (95% CI = 17.0% to 18.8%) self-reported screening. Screening uptake increased with increasing lung cancer death risk quintile (Q1 = 5.2%, 95% CI = 3.0% to 8.8%; Q5 = 21.8%, 95% CI = 20.3% to 23.3%) and life-gain from screening quintile (Q1 = 6.2%, 95% CI = 3.8% to 9.9%; Q5 = 20.8%, 95% CI = 19.5% to 22.2%). Screened individuals had higher lung cancer death risk (risk ratio [RR] = 1.35, 95% CI = 1.26 to 1.46) and life-years gained (RR = 1.19, 95% CI = 1.12 to 1.25) than unscreened individuals. Currently, screening averts 19 306 lung cancer deaths and gains 237 564 life-years; screening everyone eligible would additionally avert 56 956 lung cancer deaths and gain 751 850 life-years. Two-thirds of USPSTF lung-eligible women were up to date with breast cancer screening, but only 17.3% attended lung screening in the past year. Conclusions: Eligible screening attendees had higher lung cancer death risk and benefit from screening. Higher rates of screening could substantially increase the number of lung cancer deaths prevented.Keywords
Funding Information
- National Institutes of Health
- National Cancer Institute
- NIH
- Office of Human Subjects Research
This publication has 18 references indexed in Scilit:
- Prevalence of Lung Cancer Screening Among Eligible Adults in 4 US States in 2021JAMA Network Open, 2023
- Assessment of Uptake Appropriateness of Computed Tomography for Lung Cancer Screening According to Patients Meeting Eligibility Criteria of the US Preventive Services Task ForceJAMA Network Open, 2022
- Is Lung Cancer Screening Reaching the People Who Are Most Likely to Benefit?JAMA Network Open, 2022
- Likelihood of Lung Cancer Screening by Poor Health Status and Race and Ethnicity in US Adults, 2017 to 2020JAMA Network Open, 2022
- Screening for Lung CancerChest, 2021
- Predictors of Lung Cancer Screening Utilization in a Population-Based SurveyJournal of the American College of Radiology, 2020
- Lung Cancer Screening Uptake: Analysis of BRFSS 2018Journal of General Internal Medicine, 2020
- Comparing cancer screening estimates: Behavioral Risk Factor Surveillance System and National Health Interview SurveyPreventive Medicine, 2018
- Lung Cancer Screening With Low-Dose Computed Tomography in the United States—2010 to 2015JAMA Oncology, 2017
- Development and Validation of Risk Models to Select Ever-Smokers for CT Lung Cancer ScreeningJAMA, 2016